DekaBank Deutsche Girozentrale raised its stake in shares of Celgene Co. (NASDAQ:CELG) by 51.1% in the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 1,047,470 shares of the biopharmaceutical company’s stock after purchasing an additional 354,051 shares during the period. DekaBank Deutsche Girozentrale owned 0.15% of Celgene worth $96,921,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in the business. Berman Capital Advisors LLC boosted its stake in shares of Celgene by 11.3% in the second quarter. Berman Capital Advisors LLC now owns 1,096 shares of the biopharmaceutical company’s stock worth $101,000 after acquiring an additional 111 shares during the period. Altium Wealth Management LLC boosted its stake in shares of Celgene by 1.3% in the first quarter. Altium Wealth Management LLC now owns 8,980 shares of the biopharmaceutical company’s stock worth $847,000 after acquiring an additional 115 shares during the period. Global Retirement Partners LLC boosted its stake in Celgene by 10.0% during the first quarter. Global Retirement Partners LLC now owns 1,269 shares of the biopharmaceutical company’s stock valued at $120,000 after buying an additional 115 shares during the last quarter. MBM Wealth Consultants LLC boosted its stake in Celgene by 2.8% during the second quarter. MBM Wealth Consultants LLC now owns 4,264 shares of the biopharmaceutical company’s stock valued at $397,000 after buying an additional 116 shares during the last quarter. Finally, Community Bank N.A. boosted its stake in Celgene by 3.2% during the first quarter. Community Bank N.A. now owns 3,922 shares of the biopharmaceutical company’s stock valued at $370,000 after buying an additional 120 shares during the last quarter. 74.19% of the stock is owned by institutional investors and hedge funds.

Shares of CELG stock opened at $94.20 on Wednesday. Celgene Co. has a 1 year low of $58.59 and a 1 year high of $98.97. The company has a debt-to-equity ratio of 1.97, a quick ratio of 3.32 and a current ratio of 3.44. The company’s 50 day moving average is $92.75. The stock has a market capitalization of $66.70 billion, a P/E ratio of 12.38, a PEG ratio of 0.44 and a beta of 1.46.

Celgene (NASDAQ:CELG) last issued its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $2.61 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.44 by $0.17. Celgene had a return on equity of 89.93% and a net margin of 32.24%. The business had revenue of $4.40 billion for the quarter, compared to the consensus estimate of $4.22 billion. During the same period in the prior year, the business posted $2.16 earnings per share. The company’s quarterly revenue was up 15.4% compared to the same quarter last year. Equities research analysts expect that Celgene Co. will post 9.96 earnings per share for the current fiscal year.

A number of equities analysts recently commented on CELG shares. Barclays lowered Celgene from an “overweight” rating to an “equal weight” rating and set a $102.00 price target for the company. in a research note on Friday, May 3rd. Zacks Investment Research raised Celgene from a “sell” rating to a “hold” rating and set a $94.00 price target for the company in a research note on Tuesday, July 23rd. BidaskClub raised Celgene from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 3rd. Cowen reissued a “hold” rating and set a $102.00 price target on shares of Celgene in a research note on Tuesday, July 30th. Finally, ValuEngine lowered Celgene from a “sell” rating to a “strong sell” rating in a research note on Thursday, August 1st. Two research analysts have rated the stock with a sell rating, sixteen have issued a hold rating and four have issued a buy rating to the company’s stock. Celgene presently has an average rating of “Hold” and a consensus target price of $94.81.

Celgene Profile

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Featured Story: Do You Need a Fiduciary?

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.